Increased mortality in patients with non-functioning pituitary tumors: a study in a tertiary center

无功能性垂体瘤患者死亡率增加:一项三级中心的研究

阅读:2

Abstract

BACKGROUND INFORMATION: Most of the studies on mortality, survival analysis and predictor variables in patients with non-functioning pituitary adenomas (NFPA) are heterogeneous and limited; and in some cases, they offer contradictory results. PATIENTS AND METHODS: Our objective was to analyze the survival of 749 patients (46.3% were women) with NFPA, with a mean follow-up of 60.2 months (32.9-120.6) at a tertiary center, from March 2007 to August 2023. Descriptive and inferential statistics were used. Mortality risk was determined in comparison with the Mexican population by calculating the standardized mortality ratio (SMR) with 99% confidence intervals. Survival analysis and Cox proportional hazards (HR) analysis were performed to identify possible predictors. RESULTS: The overall SMR was of 8.86 (99% Confidence Interval [CI] 5.92-13.25, p<0.001), for <60 years-old patients, it was 13.77 (99% CI 7.23-26.23, p<0.001). In men, it was 7.08 (99% CI 3.92-12.80, p<0.001), and in women it was 11. 11 (99% CI 6.41-19.24, p<0.001). Regarding patients with arterial hypertension, we obtained 6.59 (99% CI 3.75-11.56, p<0.001), and with type 2 diabetes, it was 4.63 (99% CI 1.96-10.93, p<0.001). In the Cox analysis for mortality, an adjusted HR of 2.19 (95% CI 1.13-4.26, p=0.02) was observed for arterial hypertension and 1.32 (95% CI 1.00-1.75, p=0.04) for the total number of surgeries. The rest of the variables had no statistically significant association with mortality. CONCLUSION: Our study shows a higher mortality in patients diagnosed with NFPA compared to the general population. The higher probability of death was found in the presence of predictors such as arterial hypertension and the total number of surgeries.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。